I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Ciccarone Center Research
View by Topic
- Antiplatelet Therapy
- ASCVD (Atherosclerotic Cardiovascular Disease)
- Blood Pressure
- Cardiac CT
- Cardiovascular Risk Assessment
- Carotid Atherosclerosis
- Cerebrovascular Disease / Stroke / Cognitive Function
- Cholesterol / Lipids / Statins
- Cigarette Smoking
- Diabetes & Metabolic Syndrome
- Diet & Weight
- Disparities in Care
- Emotional Health
- Endothelial Function
- Erectile Dysfunction
- Exercise and Physical Fitness
- Family History of CVD
- Gender / Cardiovascular Disease in Women
- Heart Failure
- Heart Rate
- Markers of Thrombosis, Myocardial Injury, Wall Stress
- Mobile Health
- Nutrition, Vitamins, Supplements
- PVD – Peripheral Vascular Disease
- Quality of Care
- Renal Disease
- Rheumatoid Arthritis & Collagen Vascular Diseases
- Sleep Disorders
- Stem Cells
- Subclinical Atherosclerosis
- Vascular Imaging
- Vascular Stiffness
View by Journal
- American Heart Journal
- American Journal of Cardiology
- American Journal of Epidemiology
- American Journal of Hypertension
- Annals of Internal Medicine
- Arteriosclerosis, Thrombosis & Vascular Biology
- British Medical Journal
- Clinical Cardiology
- Diabetes Care
- European Heart Journal
- European Journal of Preventive Cardiology
- International Journal of Cardiology
- Journal of Hypertension
- Journal of the American College of Cardiology
- Journal of the American Heart Association
- Journal of the American Medical Association
- Mayo Clinic Proceedings
- New England Journal of Medicine
- PLoS One
View by Year
- Meet the Authors
Nonfatal outcomes in the primary prevention of atherosclerotic cardiovascular disease: is all-cause mortality really all that matters?Read on Pubmed
This article clearly shows that major nonfatal cardiovascular outcomes are very important to take into account when designing primary prevention guidelines.
Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients.Read on Pubmed
Subclinical atherosclerosis testing with CAC is currently superior to any combination of risk factors and serum biomarkers.
Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis Heart Trials.Read on Pubmed
This analysis looks at the strengths and limitations of two large trials of statin therapy based on persons with an elevated hsCRP, CAC score, or both.
Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.Read on Pubmed
CAC scoring can help match statin therapy to absolute atherosclerotic CVD risk.
Exercise blood pressure and future cardiovascular death in asymptomatic individuals.
Individuals with exaggerated exercise BP tend to develop future hypertension. It is controversial whether they have higher risk of death from cardiovascular disease (CVD). We found that, in asymptomatic individuals, elevated exercise BP carried higher risk of CVD death but became nonsignificant after accounting for rest BP. However, Bruce stage 2 BP >180/90 mm Hg identified nonhypertensive individuals at higher risk of CVD death.
Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group.
The National Heart, Lung, and Blood Institute convened a working group to provide basic and clinical research recommendations on the development of an integrated approach for identifying those individuals who are at high risk for a cardiovascular event, such as acute coronary syndromes (ACS) or sudden cardiac death in the “near term.” The participants reviewed current clinical cardiology practices for risk assessment and state-of-the-science techniques in several areas, including biomarkers, proteomics, genetics, psychosocial factors, imaging, coagulation, and vascular and myocardial susceptibility. This report presents highlights of these reviews and a summary of suggested research directions.
The numbers are in – statins for the primary prevention of cardiovascular disease in women.
This study indicates that statin therapy among middle-aged and older women with low LDL-C but above average hsCRP achieves better outcomes than those previously observed in primary prevention trials that were conducted with less potent statins in individuals with overt hyperlipidemia. Clearly, the evidence base for statin therapy in asymptomatic middle-aged and older women with other risk factors is now much more compelling, thanks to the work of Mora and colleagues. We await publication of the formal cost-effectiveness analyses from the landmark JUPITER data set, as well as data on the long-term safety of high-potency statin therapy. In the meantime, clinicians will undoubtedly use the data by Mora et al to prescribe statin therapy much earlier for women who meet the entry criteria of the JUPITER study, and this change will improve cardiovascular outcomes in women.
Integrative predictive model of coronary artery calcification in atherosclerosis.
Many different genetic and clinical factors have been identified as causes or contributors to atherosclerosis. We present a model of preclinical atherosclerosis based on genetic and clinical data that predicts the presence of coronary artery calcification in healthy Americans of European descent 45 to 84 years of age in the MESA study. Our investigation of joint genetic and clinical factors associated with atherosclerosis shows predictive results for both cases, as well as enhanced performance for their combination.
Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy.
Cardiosphere-derived cells (CDCs) isolated from human endomyocardial biopsies reduce infarct size and improve cardiac function in mice. Safety and efficacy testing in large animals is necessary for clinical translation. Intracoronary delivery of CDCs in a preclinical model of postinfarct left ventricular dysfunction results in formation of new cardiac tissue, reduces relative infarct size, attenuates adverse remodeling, and improves hemodynamics. The evidence of efficacy without obvious safety concerns at 8 weeks of follow-up motivates human studies in patients after myocardial infarction and in chronic ischemic cardiomyopathy.